JP2009167214A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009167214A5 JP2009167214A5 JP2009111653A JP2009111653A JP2009167214A5 JP 2009167214 A5 JP2009167214 A5 JP 2009167214A5 JP 2009111653 A JP2009111653 A JP 2009111653A JP 2009111653 A JP2009111653 A JP 2009111653A JP 2009167214 A5 JP2009167214 A5 JP 2009167214A5
- Authority
- JP
- Japan
- Prior art keywords
- polymer
- pharmaceutical composition
- poly
- polymer conjugate
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920000642 polymer Polymers 0.000 claims 39
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims 9
- 239000003401 opiate antagonist Substances 0.000 claims 8
- -1 6-amino-naloxone Chemical compound 0.000 claims 7
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- YQYVFVRQLZMJKJ-JBBXEZCESA-N (+)-cyclazocine Chemical compound C([C@@]1(C)C2=CC(O)=CC=C2C[C@@H]2[C@@H]1C)CN2CC1CC1 YQYVFVRQLZMJKJ-JBBXEZCESA-N 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 229920002125 Sokalan® Polymers 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 230000008499 blood brain barrier function Effects 0.000 claims 2
- 210000001218 blood-brain barrier Anatomy 0.000 claims 2
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims 2
- 229960001736 buprenorphine Drugs 0.000 claims 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims 2
- 229950002213 cyclazocine Drugs 0.000 claims 2
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims 2
- 230000003301 hydrolyzing effect Effects 0.000 claims 2
- 210000005027 intestinal barrier Anatomy 0.000 claims 2
- 230000004673 intestinal mucosal barrier function Effects 0.000 claims 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 2
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 claims 2
- 229960000805 nalbuphine Drugs 0.000 claims 2
- 229960004127 naloxone Drugs 0.000 claims 2
- 229960003086 naltrexone Drugs 0.000 claims 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 claims 2
- 229960005301 pentazocine Drugs 0.000 claims 2
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 claims 2
- 229960000482 pethidine Drugs 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 claims 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 1
- PCSQOABIHJXZMR-MGQKVWQSSA-O (4r,4as,7ar,12bs)-4a,9-dihydroxy-3-methyl-3-prop-2-enyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-3-ium-7-one Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CC[N+](C)(CC=C)[C@@H]3CC5=CC=C4O PCSQOABIHJXZMR-MGQKVWQSSA-O 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims 1
- XLPJNCYCZORXHG-UHFFFAOYSA-N 1-morpholin-4-ylprop-2-en-1-one Chemical compound C=CC(=O)N1CCOCC1 XLPJNCYCZORXHG-UHFFFAOYSA-N 0.000 claims 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 claims 1
- 229930008281 A03AD01 - Papaverine Natural products 0.000 claims 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 claims 1
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 claims 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims 1
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 claims 1
- 229920001389 Poly(hydroxyalkylmethacrylamide) Polymers 0.000 claims 1
- 229960001391 alfentanil Drugs 0.000 claims 1
- 229940061720 alpha hydroxy acid Drugs 0.000 claims 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 claims 1
- AKNNEGZIBPJZJG-UHFFFAOYSA-N alpha-noscapine Natural products CN1CCC2=CC=3OCOC=3C(OC)=C2C1C1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-UHFFFAOYSA-N 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 claims 1
- 229960001113 butorphanol Drugs 0.000 claims 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 claims 1
- 235000013877 carbamide Nutrition 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 238000004581 coalescence Methods 0.000 claims 1
- 229960004126 codeine Drugs 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- NLBUEDSBXVNAPB-DFQSSKMNSA-N cyclorphan Chemical compound C([C@]12CCCC[C@H]1[C@H]1CC3=CC=C(C=C32)O)CN1CC1CC1 NLBUEDSBXVNAPB-DFQSSKMNSA-N 0.000 claims 1
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 claims 1
- 229960004193 dextropropoxyphene Drugs 0.000 claims 1
- VTMVHDZWSFQSQP-VBNZEHGJSA-N dezocine Chemical compound C1CCCC[C@H]2CC3=CC=C(O)C=C3[C@]1(C)[C@H]2N VTMVHDZWSFQSQP-VBNZEHGJSA-N 0.000 claims 1
- 229960003461 dezocine Drugs 0.000 claims 1
- 229960002069 diamorphine Drugs 0.000 claims 1
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 claims 1
- 229960000920 dihydrocodeine Drugs 0.000 claims 1
- 150000002170 ethers Chemical class 0.000 claims 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 1
- 229960002428 fentanyl Drugs 0.000 claims 1
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 229920002674 hyaluronan Polymers 0.000 claims 1
- 229960003160 hyaluronic acid Drugs 0.000 claims 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 claims 1
- 229960000240 hydrocodone Drugs 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 claims 1
- 229960001410 hydromorphone Drugs 0.000 claims 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 229960003406 levorphanol Drugs 0.000 claims 1
- FQXXSQDCDRQNQE-UHFFFAOYSA-N markiertes Thebain Natural products COC1=CC=C2C(N(CC3)C)CC4=CC=C(OC)C5=C4C23C1O5 FQXXSQDCDRQNQE-UHFFFAOYSA-N 0.000 claims 1
- 229960001797 methadone Drugs 0.000 claims 1
- JVLBPIPGETUEET-GAAHOAFPSA-O methylnaltrexone Chemical compound C[N+]1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@@H]3[C@]4([C@@]2(O)CCC3=O)CC1)CC1CC1 JVLBPIPGETUEET-GAAHOAFPSA-O 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229960005181 morphine Drugs 0.000 claims 1
- 229960005297 nalmefene Drugs 0.000 claims 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical group O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims 1
- DKJCUVXSBOMWAV-PCWWUVHHSA-N naltrindole Chemical compound N1([C@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC2=C3[CH]C=CC=C3N=C25)O)CC1)O)CC1CC1 DKJCUVXSBOMWAV-PCWWUVHHSA-N 0.000 claims 1
- PLPRGLOFPNJOTN-UHFFFAOYSA-N narcotine Natural products COc1ccc2C(OC(=O)c2c1OC)C3Cc4c(CN3C)cc5OCOc5c4OC PLPRGLOFPNJOTN-UHFFFAOYSA-N 0.000 claims 1
- 229960004708 noscapine Drugs 0.000 claims 1
- 239000003402 opiate agonist Substances 0.000 claims 1
- 229960002085 oxycodone Drugs 0.000 claims 1
- 229960005118 oxymorphone Drugs 0.000 claims 1
- 229960001789 papaverine Drugs 0.000 claims 1
- 229920000765 poly(2-oxazolines) Polymers 0.000 claims 1
- 229920001390 poly(hydroxyalkylmethacrylate) Polymers 0.000 claims 1
- 229920001583 poly(oxyethylated polyols) Polymers 0.000 claims 1
- 229920002627 poly(phosphazenes) Polymers 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 229960004739 sufentanil Drugs 0.000 claims 1
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 claims 1
- 229920001897 terpolymer Polymers 0.000 claims 1
- FQXXSQDCDRQNQE-VMDGZTHMSA-N thebaine Chemical compound C([C@@H](N(CC1)C)C2=CC=C3OC)C4=CC=C(OC)C5=C4[C@@]21[C@H]3O5 FQXXSQDCDRQNQE-VMDGZTHMSA-N 0.000 claims 1
- 229930003945 thebaine Natural products 0.000 claims 1
- 150000003568 thioethers Chemical class 0.000 claims 1
- 229960004380 tramadol Drugs 0.000 claims 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims 1
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 claims 1
- 150000003672 ureas Chemical class 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33040001P | 2001-10-18 | 2001-10-18 | |
| US60/330,400 | 2001-10-18 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003535793A Division JP4814488B2 (ja) | 2001-10-18 | 2002-10-18 | 重合体共役物オピオイドアンタゴニスト |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009167214A JP2009167214A (ja) | 2009-07-30 |
| JP2009167214A5 true JP2009167214A5 (https=) | 2011-04-07 |
| JP5570137B2 JP5570137B2 (ja) | 2014-08-13 |
Family
ID=23289594
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003535793A Expired - Lifetime JP4814488B2 (ja) | 2001-10-18 | 2002-10-18 | 重合体共役物オピオイドアンタゴニスト |
| JP2009111653A Expired - Lifetime JP5570137B2 (ja) | 2001-10-18 | 2009-04-30 | 重合体共役物オピオイドアンタゴニスト |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003535793A Expired - Lifetime JP4814488B2 (ja) | 2001-10-18 | 2002-10-18 | 重合体共役物オピオイドアンタゴニスト |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US7056500B2 (https=) |
| EP (3) | EP2236161A1 (https=) |
| JP (2) | JP4814488B2 (https=) |
| KR (2) | KR100974842B1 (https=) |
| AU (1) | AU2002360284B2 (https=) |
| CA (1) | CA2463938C (https=) |
| CY (1) | CY1119906T1 (https=) |
| DK (2) | DK1436012T3 (https=) |
| ES (2) | ES2654819T3 (https=) |
| LT (1) | LT1436012T (https=) |
| MX (1) | MXPA04003597A (https=) |
| PT (2) | PT2939696E (https=) |
| SI (2) | SI1436012T1 (https=) |
| WO (1) | WO2003032990A2 (https=) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274591B1 (en) * | 1997-11-03 | 2001-08-14 | Joseph F. Foss | Use of methylnaltrexone and related compounds |
| US20030158220A1 (en) * | 1997-11-03 | 2003-08-21 | Foss Joseph F. | Use of methylnaltrexone and related compounds to treat chronic opioid use side effects |
| KR100619612B1 (ko) | 1999-10-04 | 2006-09-01 | 넥타르 테라퓨틱스 에이엘, 코포레이션 | 폴리머 안정화 신경펩타이드 |
| ES2654819T3 (es) | 2001-10-18 | 2018-02-15 | Nektar Therapeutics | Conjugados poliméricos de antagonistas de opioides |
| EE05509B1 (et) | 2002-01-18 | 2012-02-15 | Biogen@Idec@Ma@Inc | Aktiveeritud polalkleenglkoolpolmeer ja seda sisaldavad kompositsioonid |
| HRP20150037T4 (hr) | 2003-04-08 | 2022-09-02 | Progenics Pharmaceuticals, Inc. | Farmaceutske formulacije koje sadrže metilnaltrekson |
| MXPA05010819A (es) * | 2003-04-08 | 2006-03-30 | Progenics Pharm Inc | Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable. |
| US20040202717A1 (en) | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
| RU2005134364A (ru) * | 2003-04-08 | 2006-06-10 | Проджиникс Фармасьютикалз, Инк. (Us) | Комбинированное лечение запора |
| GB0314472D0 (en) | 2003-06-20 | 2003-07-23 | Warwick Effect Polymers Ltd | Polymer |
| US7482376B2 (en) | 2003-07-03 | 2009-01-27 | 3-Dimensional Pharmaceuticals, Inc. | Conjugated complement cascade inhibitors |
| EP1725572B1 (de) | 2003-11-05 | 2017-05-31 | AGCT GmbH | Makromolekulare nukleotidverbindungen und methoden zu deren anwendung |
| EP2905033B1 (en) * | 2003-12-16 | 2020-09-02 | Nektar Therapeutics | Monodisperse PEGylated naloxol compositions |
| AU2014280956B2 (en) * | 2003-12-16 | 2016-09-22 | Nektar Therapeutics | Chemically modified small molecules |
| US20060182692A1 (en) | 2003-12-16 | 2006-08-17 | Fishburn C S | Chemically modified small molecules |
| JP2007530569A (ja) * | 2004-03-23 | 2007-11-01 | アムジエン・インコーポレーテツド | 化学修飾タンパク質組成物及び方法 |
| CA2569758A1 (en) * | 2004-06-08 | 2005-12-29 | Mallinckrodt Inc. | Extraction of alkaloids from opium |
| CA2594987A1 (en) * | 2004-12-14 | 2006-06-22 | Shionogi & Co., Ltd. | Therapeutic agent for constipation |
| AU2006206454A1 (en) * | 2005-01-20 | 2006-07-27 | Progenics Pharmaceuticals, Inc. | Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction |
| US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
| ES2714198T3 (es) | 2005-03-07 | 2019-05-27 | Univ Chicago | Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales |
| US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| US8524731B2 (en) | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| AR057325A1 (es) * | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
| AR057035A1 (es) | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
| US20080194611A1 (en) * | 2005-06-03 | 2008-08-14 | Alverdy John C | Modulation of Cell Barrier Dysfunction |
| KR101421747B1 (ko) | 2006-04-21 | 2014-07-30 | 넥타르 테라퓨틱스 | 모르피논의 입체선택적 환원 |
| CA2653741C (en) | 2006-05-26 | 2015-07-07 | Thomas E. Jenkins | Controlled release of phenolic opioids |
| TWI489984B (zh) | 2006-08-04 | 2015-07-01 | Wyeth Corp | 用於非經腸道傳輸化合物之配方及其用途 |
| JP2010509227A (ja) * | 2006-11-07 | 2010-03-25 | ネクター セラピューティックス エイエル，コーポレイション | オピオイド作動薬およびオピオイド拮抗薬の用量形態および同時投与 |
| US20080176884A1 (en) * | 2006-11-22 | 2008-07-24 | Progenics Pharmaceuticals, Inc. | 7,8-Saturated-4,5-Epoxy-Morphinanium Analogs |
| US20110105381A2 (en) * | 2007-02-16 | 2011-05-05 | Pharmacofore, Inc. | Prodrugs of Peripheral Phenolic Opioid Antagonists |
| US20140011964A1 (en) | 2007-02-28 | 2014-01-09 | Serina Therapeutics, Inc. | Activated Polyoxazolines and Conjugates and Compositions Comprising the Same |
| KR101508621B1 (ko) * | 2007-02-28 | 2015-04-07 | 세리나 쎄라퓨틱스, 인코포레이티드 | 활성화된 폴리옥사졸린 및 이를 포함하는 조성물 |
| US10512644B2 (en) | 2007-03-12 | 2019-12-24 | Inheris Pharmaceuticals, Inc. | Oligomer-opioid agonist conjugates |
| US8173666B2 (en) | 2007-03-12 | 2012-05-08 | Nektar Therapeutics | Oligomer-opioid agonist conjugates |
| CA2679479C (en) * | 2007-03-12 | 2015-10-06 | Nektar Therapeutics | Oligomer-opioid agonist conjugates |
| SI2565195T1 (sl) | 2007-03-29 | 2015-09-30 | Wyeth Llc | Periferalni opioidni receptorji in antagonisti in njih uporaba |
| MX2009010550A (es) | 2007-03-29 | 2009-12-14 | Progenics Pharm Inc | Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas. |
| CL2008000905A1 (es) | 2007-03-29 | 2008-08-22 | Progenics Pharm Inc | Compuestos derivados de morfina, antagonistas del receptor opioide periferico; metodo de preparacion; composicion farmaceutica; y uso para reducir los efectos de la actividad opioide endogena. |
| US8748448B2 (en) | 2007-10-18 | 2014-06-10 | Aiko Biotechnology | Combination analgesic employing opioid agonist and neutral antagonist |
| EP2214672B1 (en) * | 2007-10-18 | 2012-10-17 | Aiko Biotechnology | Combination analgesic employing opioid and neutral antagonist |
| EP2240489A1 (en) | 2008-02-06 | 2010-10-20 | Progenics Pharmaceuticals, Inc. | Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone |
| EP2278966B1 (en) | 2008-03-21 | 2019-10-09 | The University of Chicago | Treatment with opioid antagonists and mtor inhibitors |
| MX2010011727A (es) * | 2008-05-07 | 2010-11-30 | Nektar Therapeutics | Administracion oral de antagonistas opioides que actuan perifericamente. |
| CA2729582C (en) | 2008-07-01 | 2017-09-19 | University Of Chicago | Particles containing an opioid receptor antagonist and methods of use |
| KR101671537B1 (ko) | 2008-08-11 | 2016-11-01 | 넥타르 테라퓨틱스 | 다분지형 중합체 알카노에이트 컨쥬게이트 |
| KR101660996B1 (ko) * | 2008-09-16 | 2016-09-28 | 넥타르 테라퓨틱스 | 남용에 대한 낮은 잠재성을 갖는 페길화 오피오이드 |
| CA2676881C (en) | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
| AU2010295464B2 (en) * | 2009-09-18 | 2015-11-26 | Merck Sharp & Dohme Corp. | Use of opioid receptor antagonist for gastrointestinal tract disorders |
| EP2494073B1 (de) | 2009-10-26 | 2017-11-29 | AGCT GmbH | Konjugate von nukleotiden und methoden zu deren anwendung |
| UA123856C2 (uk) | 2010-03-11 | 2021-06-16 | Уайт Елелсі | Фармацевтичні композиції метилналтрексону та натрію додецилсульфату для перорального введення |
| AU2011307608B8 (en) | 2010-09-30 | 2015-08-27 | Grünenthal GmbH | Crystalline naloxol-PEG conjugate |
| WO2012083197A1 (en) | 2010-12-17 | 2012-06-21 | Nektar Therapeutics | Water-soluble polymer conjugates of topotecan |
| WO2012088282A1 (en) | 2010-12-21 | 2012-06-28 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds |
| WO2012088422A1 (en) | 2010-12-22 | 2012-06-28 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of taxane-based compounds |
| US10894087B2 (en) | 2010-12-22 | 2021-01-19 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds |
| WO2013070617A1 (en) * | 2011-11-07 | 2013-05-16 | Nektar Therapeutics | Compositions, dosage forms, and coadministration of an opioid agonist compound and an analgesic compound |
| EP2895157A4 (en) * | 2012-09-11 | 2016-07-13 | Univ Massachusetts | NETWORKED POLYMER NANOBAU GROUPS AND USES THEREOF |
| LT2914599T (lt) | 2012-10-30 | 2018-02-12 | Nektar Therapeutics | Alfa-6-mpeg6-hidroksikodono, kaip opioidų agonistų, kieta druskos forma ir jos panaudojimas |
| US8637538B1 (en) | 2012-12-14 | 2014-01-28 | Trevi Therapeutics, Inc. | Methods for treatment of pruritis |
| US20140179727A1 (en) | 2012-12-14 | 2014-06-26 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
| US8987289B2 (en) | 2012-12-14 | 2015-03-24 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
| CA3042642A1 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| LT3137081T (lt) * | 2014-04-28 | 2018-02-26 | Orphomed, Inc. | Buprenorfino dimeras ir jo naudojimas gydant virškinamojo trakto sutrikimus |
| CA2955229C (en) | 2014-07-17 | 2020-03-10 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| WO2016064873A1 (en) | 2014-10-20 | 2016-04-28 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| WO2016064914A1 (en) * | 2014-10-20 | 2016-04-28 | Elysium Therapeutics, Inc. | Diversion-resistant opioid formulations |
| US10226456B2 (en) * | 2015-04-27 | 2019-03-12 | 3St Research Llc | Methods and compositions for preventing opioid abuse |
| US10449190B2 (en) | 2015-04-27 | 2019-10-22 | John K. Thottathil | Alpha-hydroxy carboxylic acid and derivatives and other GRAS-based prodrugs of opioids and uses thereof |
| US10017519B2 (en) | 2015-04-27 | 2018-07-10 | 3St Research Llc | Alpha-hydroxy carboxylic acid and derivatives and other GRAS based prodrugs of oxycodone and uses thereof |
| WO2017041095A1 (en) | 2015-09-03 | 2017-03-09 | Allegheny-Singer Research Institute | Hydrophilic fentanyl derivatives |
| CN107033154B (zh) * | 2016-02-02 | 2020-02-04 | 上海瀚迈生物医药科技有限公司 | 阿片受体拮抗剂缀合物及其应用 |
| EP3416644A4 (en) * | 2016-02-18 | 2020-01-29 | Virginia Commonwealth University | SYNTHETIC OPIOID PRODUCTS CONJUGATED TO NANOPARTICLES |
| CN108210933B (zh) * | 2016-12-22 | 2021-05-04 | 北京键凯科技股份有限公司 | 一种地佐辛与聚乙二醇的结合物 |
| WO2019018638A1 (en) | 2017-07-20 | 2019-01-24 | Suzhou Runxindatai Pharmaceutics Ltd Co. | PRODRUGS OF EXTENDED RELEASE OPIOID OPIOIDS RESISTANT TO ABUSE |
| JP2021531299A (ja) | 2018-07-23 | 2021-11-18 | トレビ セラピューティクス インコーポレイテッド | 慢性咳嗽、息切れ、及び呼吸困難の治療 |
| US12433883B2 (en) | 2019-03-29 | 2025-10-07 | Allegheny Singer Research Institute | Covalent modification and controlled delivery of mu opioid receptor antagonists |
| KR20220127849A (ko) | 2020-01-10 | 2022-09-20 | 트레비 테라퓨틱스, 인코포레이티드 | 날부핀의 투여 방법 |
| IT202200026703A1 (it) | 2022-12-23 | 2024-06-23 | Sintalica S R L | Composti triptamminici non allucinogeni, preparazione, composizioni farmaceutiche e relativi usi |
| WO2024227190A1 (en) * | 2023-04-28 | 2024-10-31 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Druggable formulation for mu/delta opioid antagonist for enhancing pain therapy and treatment of opioid withdrawal |
| WO2025029623A2 (en) * | 2023-07-28 | 2025-02-06 | The Children's Medical Center Corporation | Light-triggered polymer-naloxone conjugate for opioid reversal |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2433883C2 (de) | 1973-07-20 | 1986-03-27 | Research Corp., New York, N.Y. | Verwendung von physiologisch aktiven Polypeptiden |
| US4457933A (en) * | 1980-01-24 | 1984-07-03 | Bristol-Myers Company | Prevention of analgesic abuse |
| US4864781A (en) * | 1981-06-17 | 1989-09-12 | Emblin Robert T | Multiple panel metal roofing system with overlapping panel edges |
| US4366159A (en) * | 1981-09-08 | 1982-12-28 | Michael Richard Magruder | Nalbuphine-narcotic analgesic composition and method of producing analgesia |
| FR2514644A1 (fr) * | 1981-10-19 | 1983-04-22 | Sanofi Sa | Composition pharmaceutique a action antagoniste peripherique des opiaces |
| US4587046A (en) | 1982-05-18 | 1986-05-06 | The Regents Of The University Of California | Drug-carrier conjugates |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US4730048A (en) | 1985-12-12 | 1988-03-08 | Regents Of The University Of Minnesota | Gut-selective opiates |
| US4806556A (en) | 1985-12-12 | 1989-02-21 | Regents Of The University Of Minnesota | Gut-selective opiates |
| US4861781A (en) | 1986-03-07 | 1989-08-29 | The University Of Chicago | Quaternary derivatives of noroxymorphone which relieve nausea and emesis |
| US4719215A (en) | 1986-03-07 | 1988-01-12 | University Of Chicago | Quaternary derivatives of noroxymorphone which relieve nausea and emesis |
| US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| US5102887A (en) | 1989-02-17 | 1992-04-07 | Arch Development Corporation | Method for reducing emesis and nausea induced by the administration of an emesis causing agent |
| DK0386644T3 (da) | 1989-03-10 | 1997-10-13 | Hoffmann La Roche | Reagenser til bestemmelse af lægemidler |
| JPH0383914A (ja) | 1989-08-18 | 1991-04-09 | W R Grace & Co | ドラッグキャリアー |
| US5130126A (en) * | 1990-07-09 | 1992-07-14 | Nippon Oil & Fats Co., Ltd. | Polymer-drug conjugate and a method of producing it |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| JP2829794B2 (ja) * | 1991-02-08 | 1998-12-02 | エスエス製薬 株式会社 | 徐放性経口投与型プラノプロフェン製剤 |
| US5159081A (en) | 1991-03-29 | 1992-10-27 | Eli Lilly And Company | Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists |
| US5270328A (en) | 1991-03-29 | 1993-12-14 | Eli Lilly And Company | Peripherally selective piperidine opioid antagonists |
| US5250542A (en) | 1991-03-29 | 1993-10-05 | Eli Lilly And Company | Peripherally selective piperidine carboxylate opioid antagonists |
| US5281698A (en) | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
| WO1993024476A1 (en) | 1992-06-04 | 1993-12-09 | Clover Consolidated, Limited | Water-soluble polymeric carriers for drug delivery |
| US5321095A (en) | 1993-02-02 | 1994-06-14 | Enzon, Inc. | Azlactone activated polyalkylene oxides |
| DE69413955T2 (de) | 1993-03-17 | 1999-04-01 | Minnesota Mining And Mfg. Co., Saint Paul, Minn. | Aerosolzusammensetzung enthaltend einen aus ester-, amid- oder merkaptoester- derivat dispergiermittel |
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| US5434171A (en) | 1993-12-08 | 1995-07-18 | Eli Lilly And Company | Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates |
| US5629384A (en) | 1994-05-17 | 1997-05-13 | Consiglio Nazionale Delle Ricerche | Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces |
| US5650234A (en) | 1994-09-09 | 1997-07-22 | Surface Engineering Technologies, Division Of Innerdyne, Inc. | Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US5693609A (en) * | 1994-11-17 | 1997-12-02 | Eli Lilly And Company | Acylated insulin analogs |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| EP0914097B1 (en) | 1996-03-12 | 2002-01-16 | Alza Corporation | Composition and dosage form comprising opioid antagonist |
| US6214966B1 (en) | 1996-09-26 | 2001-04-10 | Shearwater Corporation | Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
| DE19651551C2 (de) | 1996-12-11 | 2000-02-03 | Klinge Co Chem Pharm Fab | Opioidantagonisthaltige galenische Formulierung |
| US6565885B1 (en) * | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
| US5972954A (en) | 1997-11-03 | 1999-10-26 | Arch Development Corporation | Use of methylnaltrexone and related compounds |
| EP1041987B1 (en) * | 1997-12-22 | 2006-04-19 | Euro-Celtique S.A. | Pharmaceutical oral dosage form comprising a combination of an opioid agonist and naltrexone |
| US6624142B2 (en) | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
| DK1411075T3 (da) | 1998-03-12 | 2008-10-27 | Nektar Therapeutics Al Corp | Fremgangsmåde til fremstilling af polymerkonjugater |
| US6703381B1 (en) * | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
| EP0995757A3 (en) | 1998-08-26 | 2002-05-22 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Bivalent inhibitors of the proteasome |
| US7060708B2 (en) | 1999-03-10 | 2006-06-13 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| US6380405B1 (en) | 1999-09-13 | 2002-04-30 | Nobex Corporation | Taxane prodrugs |
| US6451806B2 (en) | 1999-09-29 | 2002-09-17 | Adolor Corporation | Methods and compositions involving opioids and antagonists thereof |
| AU781839B2 (en) * | 1999-12-22 | 2005-06-16 | Nektar Therapeutics | Sterically hindered derivatives of water soluble polymers |
| US6413507B1 (en) | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
| EP2092936B1 (en) * | 2000-02-08 | 2013-03-20 | Euro-Celtique S.A. | Tamper-resistant oral opioid agonist formulations |
| AU2001257577A1 (en) | 2000-02-28 | 2001-09-03 | Shearwater Corporation | Water-soluble polymer conjugates of artelinic acid |
| US20010049375A1 (en) * | 2000-03-15 | 2001-12-06 | Wolfgang Sadee | Neutral antagonists and use thereof in treating drug abuse |
| US7829074B2 (en) * | 2001-10-18 | 2010-11-09 | Nektar Therapeutics | Hydroxypatite-targeting poly(ethylene glycol) and related polymers |
| EP1355671A2 (en) * | 2000-11-30 | 2003-10-29 | Nektar Therapeutics Al, Corporation | Water-soluble polymer conjugates of triazine derivatives |
| AU2002251988A1 (en) | 2001-02-20 | 2002-09-04 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
| EP1387673B1 (en) | 2001-05-11 | 2010-12-29 | Endo Pharmaceuticals Inc. | Abuse-resistant controlled-release opioid dosage form |
| US6858580B2 (en) * | 2001-06-04 | 2005-02-22 | Nobex Corporation | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| US6835802B2 (en) * | 2001-06-04 | 2004-12-28 | Nobex Corporation | Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties |
| US6756354B2 (en) * | 2001-09-05 | 2004-06-29 | Deanna Jean Nelson | Therapeutic compositions containing oligo (ethylene glycol)-terminated 1,2-dithiolanes and their conjugates |
| US20030054030A1 (en) * | 2001-09-13 | 2003-03-20 | Gary Gordon | Method and compositions for the treatment of pruritus |
| ES2654819T3 (es) | 2001-10-18 | 2018-02-15 | Nektar Therapeutics | Conjugados poliméricos de antagonistas de opioides |
| WO2003037384A2 (en) | 2001-10-29 | 2003-05-08 | Nektar Therapeutics Al, Corporation | Polymer conjugates of protein kinase c inhibitors |
| KR20050042013A (ko) * | 2001-10-30 | 2005-05-04 | 넥타르 테라퓨틱스 에이엘, 코포레이션 | 레티노산의 수용성 중합체 콘쥬게이트 |
| CA2822457C (en) | 2001-12-14 | 2016-03-08 | The University Of Wyoming | Methods and compositions for controlled resease of drugs |
| EP2316468A1 (en) | 2002-02-22 | 2011-05-04 | Shire LLC | Delivery system and methods for protecting and administering dextroamphetamine |
| JP2006520392A (ja) | 2003-03-13 | 2006-09-07 | コントロールド・ケミカルズ・インコーポレーテッド | 薬物の乱用可能性を低下させ且つ作用持続時間を延長する化合物および方法 |
| US20060182692A1 (en) * | 2003-12-16 | 2006-08-17 | Fishburn C S | Chemically modified small molecules |
| EP2905033B1 (en) | 2003-12-16 | 2020-09-02 | Nektar Therapeutics | Monodisperse PEGylated naloxol compositions |
| EP1695700A1 (en) | 2005-02-28 | 2006-08-30 | Euro-Celtique S.A. | Dosage form containing oxycodone and naloxone |
| KR101421747B1 (ko) * | 2006-04-21 | 2014-07-30 | 넥타르 테라퓨틱스 | 모르피논의 입체선택적 환원 |
| JP2010509227A (ja) | 2006-11-07 | 2010-03-25 | ネクター セラピューティックス エイエル，コーポレイション | オピオイド作動薬およびオピオイド拮抗薬の用量形態および同時投与 |
| AU2008296971B2 (en) * | 2007-09-03 | 2014-10-02 | Nanoshift, Llc | Particulate compositions for delivery of poorly soluble drugs |
| KR102612902B1 (ko) | 2016-04-22 | 2023-12-18 | 삼성디스플레이 주식회사 | 투명 전도막 및 이를 포함하는 전자 소자 |
-
2002
- 2002-10-18 ES ES02795531.9T patent/ES2654819T3/es not_active Expired - Lifetime
- 2002-10-18 US US10/274,296 patent/US7056500B2/en not_active Expired - Lifetime
- 2002-10-18 MX MXPA04003597A patent/MXPA04003597A/es active IP Right Grant
- 2002-10-18 SI SI200231089T patent/SI1436012T1/en unknown
- 2002-10-18 DK DK02795531.9T patent/DK1436012T3/en active
- 2002-10-18 EP EP10007224A patent/EP2236161A1/en not_active Withdrawn
- 2002-10-18 WO PCT/US2002/033325 patent/WO2003032990A2/en not_active Ceased
- 2002-10-18 ES ES15172363.2T patent/ES2569262T3/es not_active Expired - Lifetime
- 2002-10-18 CA CA2463938A patent/CA2463938C/en not_active Expired - Lifetime
- 2002-10-18 KR KR1020047005735A patent/KR100974842B1/ko not_active Expired - Lifetime
- 2002-10-18 EP EP15172363.2A patent/EP2939696B1/en not_active Expired - Lifetime
- 2002-10-18 LT LTEP02795531.9T patent/LT1436012T/lt unknown
- 2002-10-18 DK DK15172363.2T patent/DK2939696T3/en active
- 2002-10-18 JP JP2003535793A patent/JP4814488B2/ja not_active Expired - Lifetime
- 2002-10-18 KR KR1020097025168A patent/KR101009309B1/ko not_active Expired - Lifetime
- 2002-10-18 EP EP02795531.9A patent/EP1436012B1/en not_active Expired - Lifetime
- 2002-10-18 PT PT151723632T patent/PT2939696E/pt unknown
- 2002-10-18 AU AU2002360284A patent/AU2002360284B2/en active Active
- 2002-10-18 SI SI200231072A patent/SI2939696T1/sl unknown
- 2002-10-18 PT PT2795531T patent/PT1436012T/pt unknown
-
2006
- 2006-01-17 US US11/332,964 patent/US7662365B2/en not_active Expired - Lifetime
-
2009
- 2009-04-30 JP JP2009111653A patent/JP5570137B2/ja not_active Expired - Lifetime
- 2009-10-06 US US12/574,335 patent/US8349307B2/en not_active Expired - Fee Related
-
2012
- 2012-11-29 US US13/689,640 patent/US8617530B2/en not_active Expired - Fee Related
-
2018
- 2018-02-12 CY CY20181100170T patent/CY1119906T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009167214A5 (https=) | ||
| CA2463938A1 (en) | Polymer conjugates of opioid antagonists | |
| CA2547334A1 (en) | Methods and compositions for deterring abuse of opioid containing dosage forms | |
| JP2010511683A5 (https=) | ||
| US10314839B2 (en) | Diversion-resistant opioid formulations | |
| JP2009541320A5 (https=) | ||
| CA2446738A1 (en) | Abuse-resistant opioid dosage form | |
| JP2005530798A5 (https=) | ||
| JP2008534564A5 (https=) | ||
| JP2011515495A5 (https=) | ||
| RU2007139827A (ru) | Фармацевтические композиции для лечения боли | |
| AU2002360284A1 (en) | Polymer conjugates of opioid antagonists | |
| JP2011519930A5 (https=) | ||
| IL276462B1 (en) | Methods of producing morphinan alkaloids and derivatives | |
| WO2004045551A3 (en) | Pharmaceutical composition | |
| JP2022001608A5 (https=) | ||
| RU2012124063A (ru) | Лекарственная комбинация с теобромином и ее использование в лечении | |
| JP2007503473A5 (https=) | ||
| JP2018534319A5 (https=) | ||
| Mizukami et al. | Theoretical Studies on the Structures of Opiate Molecules | |
| Ghodse et al. | Opioid analgesics and narcotic antagonists | |
| RU2020137881A (ru) | Антагонисты периферических рецепторов опиоидов и их применения | |
| Tsurumi | The action of opiate on the intestine-especially the action of opiate on the diarrhea in mice | |
| JP2011513278A5 (https=) |